These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25392014)

  • 21. Priapism pathophysiology: clues to prevention.
    Burnett AL
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S80-5. PubMed ID: 14551582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Priapism in sickle-cell disease: a hematologist's perspective.
    Kato GJ
    J Sex Med; 2012 Jan; 9(1):70-8. PubMed ID: 21554552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway.
    Claudino MA; Franco-Penteado CF; Corat MA; Gimenes AP; Passos LA; Antunes E; Costa FF
    J Sex Med; 2009 Aug; 6(8):2187-96. PubMed ID: 19493282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline.
    Bivalacqua TJ; Allen BK; Brock GB; Broderick GA; Chou R; Kohler TS; Mulhall JP; Oristaglio J; Rahimi LL; Rogers ZR; Terlecki RP; Trost L; Yafi FA; Bennett NE
    J Urol; 2022 Jul; 208(1):43-52. PubMed ID: 35536142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using cyproterone acetate to treat recurrent ischemic priapism in a patient with sickle cell anemia as a comorbidity: a case report.
    Alshahrani A
    J Med Case Rep; 2020 Oct; 14(1):197. PubMed ID: 33081822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism.
    Bivalacqua TJ; Musicki B; Hsu LL; Gladwin MT; Burnett AL; Champion HC
    J Sex Med; 2009 Sep; 6(9):2494-504. PubMed ID: 19523035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How I manage priapism due to sickle cell disease.
    Olujohungbe A; Burnett AL
    Br J Haematol; 2013 Mar; 160(6):754-65. PubMed ID: 23293942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of erectile dysfunction in patients with sickle cell disease.
    Gani J; Radomski SB
    J Sex Med; 2011 Aug; 8(8):2123-7, quiz 2128. PubMed ID: 21791003
    [No Abstract]   [Full Text] [Related]  

  • 29. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial--the priapism in sickle cell study.
    Olujohungbe AB; Adeyoju A; Yardumian A; Akinyanju O; Morris J; Westerdale N; Akenova Y; Kehinde MO; Anie K; Howard J; Brooks A; Davis VA; Khoriatry AI
    J Androl; 2011; 32(4):375-82. PubMed ID: 21127308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series.
    Idowu M; Garcia RL; Sule OB
    J Investig Med High Impact Case Rep; 2023; 11():23247096231191873. PubMed ID: 37731262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sickle cell disease with recurrent priapism.
    Khot R; Aher A
    J Assoc Physicians India; 2012 Nov; 60():62-3. PubMed ID: 23767208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and Characteristics of Priapism in Sickle Cell Disease.
    Arduini GAO; Trovó de Marqui AB
    Hemoglobin; 2018 Mar; 42(2):73-77. PubMed ID: 29745276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of priapism in sickle-cell diseases with alpha-adrenergic agonists].
    Gbadoé AD; Koffi KS; Akakpo-Maxwell O; Lawson-Evi K; Guédéhoussou T; Assimadi JK
    Sante; 2002; 12(3):343-7. PubMed ID: 12473531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial Effect of the Nitric Oxide Donor Compound 3-(1,3-Dioxoisoindolin-2-yl)Benzyl Nitrate on Dysregulated Phosphodiesterase 5, NADPH Oxidase, and Nitrosative Stress in the Sickle Cell Mouse Penis: Implication for Priapism Treatment.
    Silva FH; Karakus S; Musicki B; Matsui H; Bivalacqua TJ; Dos Santos JL; Costa FF; Burnett AL
    J Pharmacol Exp Ther; 2016 Nov; 359(2):230-237. PubMed ID: 27540002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenosine signaling, priapism and novel therapies.
    Dai Y; Zhang Y; Phatarpekar P; Mi T; Zhang H; Blackburn MR; Xia Y
    J Sex Med; 2009 Mar; 6 Suppl 3():292-301. PubMed ID: 19267852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multisystem damage associated with tricorporal priapism in sickle cell disease.
    Sharpsteen JR; Powars D; Johnson C; Rogers ZR; Williams WD; Posch RJ
    Am J Med; 1993 Mar; 94(3):289-95. PubMed ID: 8452153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Priapism: Diagnosis and management].
    Carnicelli D; Akakpo W
    Prog Urol; 2018 Nov; 28(14):772-776. PubMed ID: 30201552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism.
    Levine LA; Guss SP
    J Urol; 1993 Aug; 150(2 Pt 1):475-7. PubMed ID: 8326584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sickle cell disease priapism: treatment with intracavernous injections of etilefrine].
    Gbadoe AD; Akakpo-Vidah A; Pitche P; Assimadi JK
    Med Trop (Mars); 2000; 60(1):53-6. PubMed ID: 10989788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitric oxide in the penis--science and therapeutic implications from erectile dysfunction to priapism.
    Burnett AL
    J Sex Med; 2006 Jul; 3(4):578-582. PubMed ID: 16839312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.